Subscribe
shutterstock_1155156751_atmosphere1
Atmosphere1 / Shutterstock.com
29 September 2022Big PharmaMuireann Bolger

MSD prevails in diabetes drug dispute with Mylan

MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Generics
MSD, Pfizer try to stop three Steglatro generics
29 March 2022   Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.
Generics
MSD hit with €39m fine over contraceptive generic delay
26 October 2022   The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Generics
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Generics
MSD, Pfizer try to stop three Steglatro generics
29 March 2022   Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.
Generics
MSD hit with €39m fine over contraceptive generic delay
26 October 2022   The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

More on this story

Generics
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Generics
MSD, Pfizer try to stop three Steglatro generics
29 March 2022   Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.
Generics
MSD hit with €39m fine over contraceptive generic delay
26 October 2022   The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers